Article
Genomic profiling in a homogeneous molecular subtype of non-small cell lung cancer: An effort to explore new drug targets.
Indian journal of cancer - 1 Jan 2000
Veldore Vidya H, Patil S, Satheesh C T, Shashidhara H P, Tejaswi R, Prabhudesai Shilpa A, Krishnamoorthy N, Hazarika D, Naik R, Rao Raghavendra M, Ajai Kumar B S
Abstract excerpt
BACKGROUND: Patients' who are positive for kinase domain activating mutations in epidermal growth factor receptor (EGFR) gene, constitute 30-40% of non-small cell lung cancer (NSCLC), and are suitable candidates for Tyrosine Kinase Inhibitor based targeted/personalized therapy. In EGFR non-mutated subset, 8-10% that show molecular abnormalities such as EML4-ALK, ROS1-ALK, KIP4-ALK, may also derive the benefit of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.